Dawnrays Pharmaceutical (Holdings) Limited (2348.HK)
- Previous Close
1.170 - Open
1.170 - Bid 1.140 x --
- Ask 1.170 x --
- Day's Range
1.170 - 1.170 - 52 Week Range
0.980 - 1.400 - Volume
40,000 - Avg. Volume
298,676 - Market Cap (intraday)
1.755B - Beta (5Y Monthly) 0.72
- PE Ratio (TTM)
5.09 - EPS (TTM)
0.230 - Earnings Date Mar 22, 2024
- Forward Dividend & Yield 0.08 (6.84%)
- Ex-Dividend Date May 28, 2024
- 1y Target Est
--
Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally. It operates in two segments, Intermediates and Bulk Medicines, and Finished Drugs. The company offers antibiotics, including pharmaceutical intermediates, bulk medicines, powder for injections, and oral antibiotics. It also provides and system specific medicines comprising cardiovascular systems; anti-allergic, anti-HBV, and digestive systems; urinary systems; and anti-pyretic analgesic, respiratory, and endocrine system drugs in the form of tablets, capsules, and granules. Dawnrays Pharmaceutical (Holdings) Limited was founded in 1995 and is headquartered in Wan Chai, Hong Kong.
www.dawnrays.com1,143
Full Time Employees
December 31
Fiscal Year Ends
Sector
Related News
Performance Overview: 2348.HK
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2348.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2348.HK
Valuation Measures
Market Cap
1.76B
Enterprise Value
732.79M
Trailing P/E
4.99
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.41
Price/Book (mrq)
0.57
Enterprise Value/Revenue
0.64
Enterprise Value/EBITDA
1.47
Financial Highlights
Profitability and Income Statement
Profit Margin
28.32%
Return on Assets (ttm)
4.73%
Return on Equity (ttm)
11.71%
Revenue (ttm)
1.15B
Net Income Avi to Common (ttm)
326M
Diluted EPS (ttm)
0.230
Balance Sheet and Cash Flow
Total Cash (mrq)
1.17B
Total Debt/Equity (mrq)
4.22%
Levered Free Cash Flow (ttm)
-217.18M
Research Analysis: 2348.HK
Company Insights: 2348.HK
2348.HK does not have Company Insights